Skip to main content

Table 1 Baseline characteristics of the 101 patients with bone marrow metastatic neuroblastoma

From: Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification

Characteristic Total [cases (%)]
Age (months)
 < 18 16 (15.8)
 ≥ 18 85 (84.2)
Sex
 Male 57 (56.4)
 Female 44 (43.6)
WBC (× 109/L)
 > 10 17 (16.8)
 4–10 60 (59.4)
 < 4 24 (23.8)
Hemoglobin (g/L)
 > 120 8 (7.9)
 90–120 59 (58.4)
 60–89 33 (32.7)
 < 60 1 (1.0)
Platelet (× 109/L)
 > 300 47 (46.5)
 100–300 48 (47.5)
 < 100 6 (6.0)
Risk stratification
 Low-risk 1 (1.0)
 Intermediate-risk 7 (6.9)
 High-risk 93 (92.1)
Primary tumor site
 Abdomen 88 (87.1)
 Thorax 12 (11.9)
 Neck 1 (1.0)
11q23 deletion
 Yes 40 (39.6)
 No 61 (60.4)
MYCN amplification
 Yes 12 (11.9)
 No 89 (88.1)
LDH (IU/L)
 < 1500 79 (78.2)
 ≥ 1500 22 (21.8)
NSE (ng/mL)
 < 370 60 (59.4)
 ≥ 370 41 (40.6)
Event
 No event 49 (48.5)
 Relapse/progression 13 (12.9)
 Death 39 (38.6)
  1. WBC white blood cell, MYCN the v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog, LDH lactate dehydrogenase, NSE neuron-specific enolase